The DEA’s June 29 Hearing Explained: What Full Cannabis Rescheduling Would Mean for Medical Patients
A federal DEA hearing beginning June 29, 2026 will determine whether all cannabis -- not just state-licensed medical marijuana -- moves from Schedule I to Schedule III. Here's what already changed on April 28, what the hearing is actually deciding, and…
President Trump’s Administration Reclassifies State-Licensed Medical Marijuana as Lower-Risk Drug
The state-licensed medical marijuana reclassified as lower-risk drug marks a significant policy shift by the Trump administration. This change may reduce regulatory barriers and expand research opportunities. Clinicians should monitor its impact on…
Colorado Business Owners Discuss Marijuana Reclassification Opportunities
The Colorado marijuana reclassification impact is creating new opportunities for business owners and researchers alike. This federal shift to Schedule III could accelerate clinical research and alter regulatory compliance. Colorado stakeholders are…
Trump Administration Advances Marijuana Rescheduling | Brownstein
The Trump administration marijuana rescheduling effort marks a pivotal shift in federal cannabis policy. This change could enable more standardized research and insurance coverage. Clinicians should monitor these developments closely for their impact on…
UNLV Scientists Discuss Federal Marijuana Reclassification Impact
Federal marijuana reclassification research impact is a pivotal topic for clinical studies. UNLV scientists highlight how this shift could remove barriers and expand research access. This change promises to accelerate evidence generation for therapeutic…
Trump Urges Congress to Address Federal Hemp Product Ban
The federal hemp product ban is creating uncertainty for patient access and clinical care. Trump calls on Congress to fix the law imposing this forthcoming ban. Clinicians must monitor regulatory changes closely to ensure treatment continuity.
How US Marijuana Reclassification Step Will Boost The $47 Billion Cannabis Industry
The marijuana federal reclassification impact 2026 marks a pivotal shift in cannabis policy. This change is expected to accelerate clinical trials and expand research opportunities. It will significantly boost the $47 billion cannabis industry by…
DOJ Moves to Loosen Cannabis Restrictions, Signals Shift Toward Rescheduling
The DOJ cannabis policy changes signal a significant shift toward rescheduling cannabis. This move could transform federal research and clinical practice. It promises to reduce legal barriers and improve patient access.
Cotton: Change to marijuana drug classification ‘a step in the wrong direction’
The cannabis drug classification debate highlights significant clinical and regulatory challenges. Opposition to DEA reclassification affects research access and patient care pathways. Clinicians must navigate this evolving policy landscape carefully.
Local Cannabis CEO Reacts to Federal Marijuana Reclassification
The federal marijuana reclassification impact marks a pivotal shift in cannabis medicine. This change from Schedule I to Schedule II opens new research opportunities while maintaining regulatory oversight. Healthcare providers should monitor evolving…